← All trials
NCT03938857
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 29, 2019
- Primary completion
- Jul 28, 2020
- Completion date
- Aug 28, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 48
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Duke UniversityLead sponsor
- National Institutes of Health (NIH)Collaborator
- Duke UniversityOverall official - principal investigator
- Johns Hopkins UniversityCollaborator
- Vanderbilt UniversityCollaborator
- Allegiance HealthCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.